Purpose: This meta-analysis investigated pemetrexed-based doublet compared with pemetrexed alone as second-line therapy for patients with advanced non-small cell lung cancer. Methods: Randomized controlled trials which compared pemetrexed-based doublet with single-agent pemetrexed in patients as second-line treatment of advanced non-small cell lung cancer were searched. Overall survival (OS) was the primary end point, while secondary end points included progression-free survival, overall response rate, 1-year survival rate, and grade 3 or 4 toxicity. Results: Four eligible randomized clinical trials including 1,084 patients were selected. Meta-analysis demonstrated that pemetrexed-based doublet arm signifi cantly improved the overall response rate (OR=2.70, 95% CI: 1.76-4.15, p=0.000), compared with docetaxel alone group, while there were no signifi cant differences in overall survival (HR=0.88, 95% CI: 0.74-1.04, p=0.132), progression-free survival (HR=0.91, 95% CI: 0.73-1.15, p=0.443), and 1-year survival rate (OR=1.43, 95% CI: 0.85-2.40, p=0.178) between the two arms. However, there were more frequencies of grade 3-4 leucopenia (OR=2.86, 95% CI: 1.32-6.20, p=0.008), neutropenia (OR=2.69, 95% CI: 1.55-4.68, p=0.000) and thrombocytopenia (OR=6.92, 95% CI: 2.51-19.07, p=0.000) in pemetrexed-based doublet group. Grade 3-4 anemia (OR=0.62, 95% CI: 0.33-1.18, p=0.144) and fatigue (OR=1.15, 95% CI: 0.73-1.79, p=0.550) had equivalent incidences in the two groups. Conclusions: This is the fi rst meta-analysis to compare pemetrexed-based doublet with single-agent pemetrexed in second-line therapy of non-small cell lung cancer. Our meta-analysis suggested that pemetrexed combination chemotherapy was not superior to single-agent arm and was not recommended as the second-line chemotherapy for patients with non-small cell lung cancer (Tab. 2, Fig. 6, Ref. 20). Text in PDF www.elis.sk. Key words: non-small-cell lung cancer, docetaxel, second-line therapy, meta-analysis. Lung cancer is one of the most common malignancies worldwide both in incidence and mortality, and leads in causing cancerrelated deaths throughout the world (1, 2). Non-small-cell lung cancer (NSCLC), including squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma accounts for approximately 80 % of all lung tumors, while 65-80 % of them present as local advanced or metastatic disease (3, 4). Less than 5 % of the fi ve-year survival rate is detected in stages IIIB and IV NSCLC patients (5). The treatment for local advanced or metastatic lung cancer is limited. Since surgical excision is impossible in most patients, chemotherapy remains the mainstay of treatment (2).
Lung cancer is one of the most common malignancies worldwide both in incidence and mortality, and leads in causing cancerrelated deaths throughout the world (1, 2) . Non-small-cell lung cancer (NSCLC), including squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma accounts for approximately 80 % of all lung tumors, while 65-80 % of them present as local advanced or metastatic disease (3, 4) . Less than 5 % of the fi ve-year survival rate is detected in stages IIIB and IV NSCLC patients (5) . The treatment for local advanced or metastatic lung cancer is limited. Since surgical excision is impossible in most patients, chemotherapy remains the mainstay of treatment (2) .
For recurrent NSCLC patients, second-line chemotherapy is necessary. Docetaxel alone is the current standard for second-line treatment of advanced NSCLC, which can prolong survival after platinum-based chemotherapy (6, 7) . However, in a randomized phase III trial, Nasser Hanna et al (8) compared the effi cacy and toxicity of pemetrexed versus docetaxel in advanced NSCLC patients previously treated with chemotherapy, and concluded that patients treated with pemetrexed have equivalent effi cacy outcomes and fewer side effects compared with those obtained with docetaxel. Barlési F et al (9) also confi rmed that docetaxel and pemetrexed shared comparable effi cacy, however with a presumably better safety profi le in case of pemetrexed. Accordingly, pemetrexed has been approved to be a standard treatment option of second-line therapy in NSCLC (10). Either docetaxel monotherapy or pemetrexed alone has several limitations with median survival times of approximately 8 months and 1-year survival of 30 % (11) .
Combination chemotherapy may be one of the considerable measures possibly combining several different kinds of agents and enhancing the anti-tumor effect. On the basis of this strategy, several randomized trials have been conducted to compare p emetrexed-based doublet with pemetrexed alone chemotherapy for the second-line treatment of advanced non-small-cell lung cancer (11, 12) . However, the conclusions of some studies are contradictory, the sample size in each single trial is small, and the statistical power is inadequate. The latter drawbacks will conceal the potentially relevant differences in effi cacy.
The aim of this meta-analysis including 4 randomized controlled trials is to compare the effi cacy and adverse events of p emetrexed-based doublet with single-agent p emetrexed, and to assess whether pemetrexed-based doublet has an increased effi cacy as second-line therapy in the treatment of patients with advanced NSCLC.
Methods

Literature search
To ensure the retrieval of all possible trials, we searched the electronic database of PubMed (up to F ebruary 2012) and Embase (1980 ( -February 2012 and the Cochrane Register of Controlled Trials as well as abstracts from the conference proceedings of the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) in recent 10 years. The following different combinations of keywords were used for the search: "NSCLC", "p emetrexed", "second-line therapy", "randomized". The published languages were not limited. The citation list from relevant review articles and selected studies were also manually searched.
Selection criteria
In order to screen the relevant clinical trials, the following inclusion criteria were performed: (a) patients with pathological confi rmation of NSCLC in clinical III-IV stage and previously treated; (b) clinical trials comparing pemetrexed alone with pemetrexed-based doublet chemotherapy; (c) phase II and III randomized controlled trials (RCT); (d) the study with suffi cient data for extraction of O S, progression-free survival (PFS), overall response rate (ORR), 1-year survival rate and grade 3 or 4 toxicity. The e xclusion criteria were trials that were ongoing studies, interim analyses, brief communication and non-randomized studies such as retrospective studies, letters to the editor, and reviews.
Quality assessment
Jadad composite scale reported by Moher D et al (13) was the standard to assess the quality of the e ligible studies in the meta analysis, which was a fi ve-point scale according to following three questions as to: (a) whether an appropriate randomization method was reported (0-2 scores); (b) whether an appropriate blinding method was reported (0-2 scores); (c) whether withdrawals and dropouts were reported (0-1 scores).
Data extraction
The following data were extracted from each of the eligible studies: basic information such as fi rst author's name, publication year, journal name, characteristics of patients (sex, age and study duration), follow-up period, inclusion and exclusion criteria, study design, sample size per arm, number of cases and eligibility for evaluation, chemotherapy regimens, doses and schedules of chemotherapy, withdrawals, OS, PFS, ORR, 1-year survival rate and adverse events (AEs). All above information was extracted independently by two investigators and verifi ed in accordance with the inclusion criteria. The primary end point was the overall survival (OS). Secondary end points included progression-free survival (PFS), overall response rate (ORR), 1-year survival rate, and grade 3 or 4 toxicity.
Data analysis and statistical methods
The Hazard ratio (HR) was used to estimate the overall survival (OS) and progression-free survival (PFS). And the odds ratio (OR) was used for overall response rate, 1-year survival rate, and grade 3 or 4 toxicity. Data analyses were conducted with Stata version 11.0 software (Stata Corporation, College Station, TX, USA) and values of p<0.05 were considered statistically signifi cant. HR>1 refl ects more deaths or progression in the p emetrexed-based doublet chemotherapy schedule while OR>1 refl ects more toxicities, 1-year survival rate, and overall response rate in pemetrexed-based doublet arm. The heterogeneity was calculated using the chi-square based Q-test (p<0.05 or I 2 >50% was considered statistically signifi cant). Sensitivity analyses were performed to test the possible reasons of heterogeneity in several studies such as study quality, study design and ethnic composition. When heterogeneity was considered statistically signifi cant, a random-effects model was used to analyze the data in meta-analysis. While he terogeneity was absent, a fi xed-effects model was used. Begg and Egger tests were used to evaluate publication bias, in which a funnel plot could show whether there was a bias. Statistical tests for heterogeneity, effect estimates, and publication bias were two-sided.
Results
Study characteristics
The fl ow chart is showed in Figure 1 . Finally, four trails were eligible for meta-analysis (11, 12, 14, 15) , while one was Phase III trial and three were phase II trials. There were 1 ,084 patients in these four trails for data analysis. Pemetrexed-based doublet chemotherapy regimens in the four trails were as follows: pemetrexed and carboplatin (11); pemetrexed and enzastaurin (14) ; pemetrexed and vandetanib (15); pemetrexed and matuzumab (12) . In two RCT trails (14, 15) , regimens of pemetrexed alone groups were pemetrexed plus placebo, while the other two trails (11, 12) did not have placebo. All four trails compared pemetrexed alone with pemetrexed-based doublet regimens. The characteristics of these studies are listed in Table 1 . Jadad scores were 3, 4, 5, 3 points, respectively.
Overall survival
The pooled HR for OS showed that t here was no signifi cant difference in overall survival between pemetrexed-based doublets with pemetrexed alone arm (HR=0.88, 95% CI: 0.74-1.04, p=0.132) (Fig. 2) . Test for heterogeneity did not show signifi cant difference (p=0.622), and fi xed-effort model was used to calculate pooled HR for OS.
Progression-free survival
The pooled HR for PFS did not show signifi cant difference in progression-free survival between pemetrexed-based doublets regi- mens group with single-agent pemetrexed group (HR=0.91, 9 5% CI: 0.73-1.15, p=0.443) (Fig. 3) . Test for heterogeneity showed that there was signifi cant difference (p=0.030), and random-effort model was used to calculate pooled HR for PFS.
Overall response rate
The pooled OR for ORR showed that there was signifi cant difference in overall response rate between pemetrexed-based doublets and pemetrexed alone group (p emetrexed-based doublet group signifi cantly improved overall response rate) (OR=2.70, 95% CI: 1.76-4.15, p=0.000) (Fig. 4) . Test for heterogeneity did not show signifi cant difference (p=0.910), while fi xed-effort model was used to calculate pooled OR for ORR.
1-year survival rate
The pooled OR for 1-year survival rate showed that there was no signifi cant difference in 1-year survival rate between pemetrexed-based doublets and pemetrexed alone group (OR=1.43, 95% CI: 0.85-2.40, p=0.178) (Fig. 5) . Test for heterogeneity showed that there was signifi cant difference (p=0.014), while random-effort model was used to calculate pooled OR for 1-year survival rate.
Safety
The pooled OR for g rade 3-4 leucopenia, neutropenia and thrombocytopenia showed that t here were statistically significantly higher frequencies in pemetrexed-based doublet group than in single-agent pemetrexed arm (OR=2.86, 95% CI: 1.32-6.20, p=0.008; O R=2.69, 95% CI: 1.55-4.68, p=0.000; OR=6.92, 95% CI: 2.51-19.07, p=0.000; respectively) (Tab. 2). The pooled OR for grade 3-4 anemia and fatigue showed that there were no statistically signifi cant differences in frequencies of anemia and fatigue between the two groups (OR=0.62, 95% CI: 0.33-1.18, p=0.144; OR=1.15, 95% CI: 0.73-1.79, p=0.550; respectively).
Publication bias
There was on publication bias according to funnel plot (Begg's test, p=0.308; Egger test, p=0.468) (Fig. 6 ).
Discussion
Progression is nearly inevitable in advanced NSCLC patients, and a pproximately thirty to forty percent of those patients received second-line c hemotherapy after standard fi rst-line treatment (16, 17) . Due to similar clinical effi cacy and signifi cantly fewer side effects, s ingle-agent pemetrexed was recommended as the s econd-line treatment for recurrent NSCLC patients. Pemetrexed is a novel chemotherapeutic drug that could inhibit the thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase to prevent tumor cell growth (8) . However, the response rate in second-line treatment of N SCLC is low (less than 10% with c hemotherapy) and survival time is limited (18, 19) .
One of the possible logical strategies to improve the effi cacy of second-line treatment is combination chemotherapy. In 2007 Weiss et al (20) reported that in their retrospective single institution analysis with pemetrexed and bevacizumab failed after fi rstline therapy compared with pemetrexed alone in patients with advanced NSCLC. The results showed that there were no significant differences in overall survival (p=0.798) and TTP (time to progression) (p=0.6125) between pemetrexed and bevacizumab group with pemetrexed alone arm, and there were no grade 3-5 bleeding events reported. However, the study had a small sample size of 25 patients and was not RCTs but retrospective study. For that reason, this study had insuffi cient power to detect whether p emetrexed-based doublet was superior to single-agent p emetrexed as second-line treatment for NSCLC. Therefore, a meta-analysis of pemetrexed or pemetrexed-based doublet therapy should be performed in order to contribute to NSCLC treatment fi elds. The purpose of our meta-analysis was to assess whether patients could gain more benefi t from pemetrexed-based doublet compared with single-agent in second-line treatment of NSCLC.
Our results showed that there were no signifi cant differences between p emetrexed-based doublet and single-agent p emetrexed in OS (HR=0.88, 95% CI: 0.74-1.04, p=0.132), PFS (HR=0.91, 95% CI: 0.73-1.15, p=0.443) and 1-year survival rate (OR=1.23, 95% CI: 0.96-1.58, p=0.100). This indicates that p emetrexed-based More adverse events were detected in p emetrexed-based doublet arm. The meta-analysis showed that there were more frequent adverse events including leucopenia (OR=2.86, 95% CI: 1.32-6.20, p=0.008), neutropenia (OR=2.69, 95% CI: 1.55-4.68, p=0.000) and thrombocytopenia (OR=6.92, 95% CI: 2.51-19.07, p=0.000) in pemetrexed-based doublet group, while grade 3-4 anemia and fatigue in pemetrexed-based doublet arm were equivalent in frequencies compared with those in single-agent therapy.
The interpretation of results of our meta-analysis should be cautious because the study included only four RCTs, they contained small number of patients, and the 1-year survival rate in all four eligible RCTs were deciphered from the survival curve due to lack of this information in above four literatures. Although there were limitations in our analysis, it may assist us, oncologists, in proper cognition of effi cacy and toxicity of p emetrexed-based doublet c hemotherapy in advanced NSCLC. We reviewed literature in English and found that there was no meta-analysis similar to ours. Thus, our study was the fi rst meta-analysis to compare tpemetrexed-based doublet with single-agent pemetrexed in second-line therapy of NSCLC.
In conclusion, despite the fact that our meta-analysis showed a markedly increased ORR in pemetrexed-based doublet arm, p emetrexed combination chemotherapy was not recommended as the second-line chemotherapy for patients of NSCLC due to lack of survival benefi t and increased toxicity.
